Evidence map›Paper›PMID 40698310›Full record

ArticleCJC open2025

Outcomes of Surgical Myectomy and Mitral Valve Repair for Hypertrophic Cardiomyopathy With vs Without Marked Septal Hypertrophy.

Kenza Rahmouni, Hugo M N Issa, Omar Toubar, Andrew M Crean, Anne Williams, Hanh Nguyen, Menaka Ponnambalam, Juan Grau, Sean Dickie, Gyaandeo Maharajh and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenza RahmouniDivision of Cardiac Surgery, Department of Surgery, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
Hugo M N IssaDivision of Cardiac Surgery, Department of Surgery, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
Omar ToubarFaculty of Medicine, McGill University, Montreal, Quebec, Canada.
Andrew M CreanDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
Anne WilliamsDivision of Cardiology, Department of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
Hanh NguyenDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
Menaka PonnambalamDivision of Cardiac Surgery, Department of Surgery, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
Juan GrauDivision of Cardiothoracic Surgery, The Valley Hospital, Ridgewood, New Jersey, USA.
Sean DickieDivision of Cardiac Anesthesia and Critical Care Medicine, Department of Anesthesia, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.
Gyaandeo MaharajhDivision of Cardiovascular Surgery, Department of Surgery, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Marc RuelDivision of Cardiac Surgery, Department of Surgery, University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study reports a single institution's clinical and echocardiographic outcomes for septal myectomy with vs without concomitant mitral valve interventions in patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction. Methods: Consecutive patients who underwent transaortic septal myectomy with vs without subvalvular mitral apparatus intervention for HCM between October 2019 and March 2024 were included. All patients underwent transesophageal echocardiography and cardiac magnetic resonance imaging to confirm the pathology, measure intracavitary gradients, and assess mitral valve morphology. Patients were analyzed as an entire cohort and stratified by the presence of marked (> 15 mm) or only mild (≤ 15 mm) septal hypertrophy. Results: A total of 61 patients (32 male) were included, of whom 28 (45.9%) had mild septal hypertrophy. The follow-up assessment was 100% complete and averaged 26.9 ± 16.2 months. In addition to septal myectomy, 32 patients (52.5%) underwent concomitant papillary muscle realignment, and aberrant chordae were resected in 40 patients (65.6%). All patients with a septal thickness ≤ 15 mm had a mitral valve repair intervention. The 30-day and 2-year mortality were 1.6% and 3.3%, respectively. No postoperative ventricular septal defects occurred, including in the thin septum subgroup. Peak LVOT gradients were significantly reduced with surgery, both at rest (47.8 ± 34.7 mm Hg preoperatively vs 8.8 ± 12.3 mm Hg postoperatively, Conclusions: In patients with symptomatic HCM, even in those without marked septal hypertrophy, septal myectomy with a concomitant mitral valve apparatus intervention is safe and provides excellent relief of LVOT obstruction.

Identifiers

PMID40698310
PMCPMC12277839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.